On the pathway to better birth outcomes? A systematic review of azithromycin and curable sexually transmitted infections

Expert Review of Anti-Infective Therapy

Volumn 11, Issue 12, 2013, Pages 1303-1332

  Matthew Chico, R ^a   Hack, Berkin B ^b   Newport, Melanie J ^b   Ngulube, Enesia ^a   Chandramohan, Daniel ^a  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^b BRIGHTON AND SUSSEX MEDICAL SCHOOL   (United Kingdom)

Author keywords

Azithromycin; Bacterial vaginosis; Chlamydia; Gonorrhea; Malaria; Pregnancy; Reproductive tract infections; Sexually transmitted infections; Sub Saharan Africa; Syphilis; Trichomoniasis

Indexed keywords

ANTHELMINTIC AGENT; AZITHROMYCIN; BENZANTHINE PENICILLIN G; CEFIXIME; CEFTRIAXONE; CIPROFLOXACIN; CLINDAMYCIN; DOXYCYCLINE; ERYTHROMYCIN; MACROLIDE; METRONIDAZOLE; MULTIVITAMIN; PENICILLIN DERIVATIVE; PLACEBO; PYRIMETHAMINE PLUS SULFADOXINE; TETRACYCLINE DERIVATIVE; UNCLASSIFIED DRUG;

ANTIBIOTIC RESISTANCE; CHLAMYDIA TRACHOMATIS; CHLAMYDIASIS; CLINICAL TRIAL (TOPIC); DELIVERY; DISEASE TRANSMISSION; DRUG EFFICACY; DRUG SENSITIVITY; DRUG TREATMENT FAILURE; ENDEMIC DISEASE; GENE MUTATION; GENITAL TRACT INFECTION; GONORRHEA; HIGH RISK POPULATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LABORATORY TEST; MINIMUM BACTERICIDAL CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; MULTICENTER STUDY (TOPIC); NEISSERIA GONORRHOEAE; OUTCOME ASSESSMENT; PREGNANCY OUTCOME; PREGNANT WOMAN; PRENATAL CARE; PROTECTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SECOND TRIMESTER PREGNANCY; SEXUALLY TRANSMITTED DISEASE; SINGLE DRUG DOSE; SYPHILIS; SYSTEMATIC REVIEW; TREATMENT DURATION; TREPONEMA PALLIDUM; TRICHOMONAS VAGINALIS; TRICHOMONIASIS; VAGINITIS; WORLD HEALTH ORGANIZATION;

ADULT; ANTI-BACTERIAL AGENTS; AZITHROMYCIN; CLINICAL TRIALS AS TOPIC; DRUG COMBINATIONS; DRUG RESISTANCE, BACTERIAL; FEMALE; HUMANS; MALARIA, FALCIPARUM; MALE; PREGNANCY; PREGNANCY OUTCOME; PYRIMETHAMINE; REPRODUCTIVE TRACT INFECTIONS; SEXUALLY TRANSMITTED DISEASES; SULFADOXINE; TREATMENT OUTCOME; VAGINOSIS, BACTERIAL;

EID: 84888043953     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/14787210.2013.851601     Document Type: Review

References (213)

1. WHO. WHO Policy Recommendation: Intermittent Preventive Treatment of Malaria in Pregnancy using Sulfadoxine-Pyrimethamine (IPTp-SP). 11 April 2013 (2013).
2. World Health Organization. World malaria report: 2012. World Health Organziation, Geneva (2012).
3. Chico RM and Chandramohan D. Intermittent preventive treatment of malaria in pregnancy: at the crossroads of public health policy. Trop. Med. Int. Health 16(7), 774-785 (2011).
4. Harrington WE, Mutabingwa TK, Muehlenbachs A et al. Competitive facilitation of drug-resistant Plasmodium falciparum malaria parasites in pregnant women who receive preventive treatment. Proc. Natl Acad. Sci. USA 106(22), 9027-9032 (2009).
5. Harrington WE, Mutabingwa TK, Kabyemela E, Fried M and Duffy PE. Intermittent treatment to prevent pregnancy malaria does not confer benefit in an area of widespread drug resistance. Clin. Infect. Dis. 53(3), 224-230 (2011).
6. Harrington WE, Morrison R, Fried M and Duffy PE. Intermittent preventive treatment in pregnant women is associated with increased risk of severe malaria in their offspring. PLoS ONE, 8(2), e56183 (2013).
7. Whitman MS and Tunkel AR. Azithromycin and clarithromycin: overview and comparison with erythromycin. Infect. Control Hosp. Epidemiol. 13(6), 357-368 (1992).
8. Chico RM, Pittrof R, Greenwood B and Chandramohan D. Azithromycin- chloroquine and the intermittent preventive treatment of malaria in pregnancy. Malar. J. 7(1), 255 (2008).
9. Sarkar M, Woodland C, Koren G and Einarson AR. Pregnancy outcome following gestational exposure to azithromycin. BMC Pregnancy Childbirth 6, 18 (2006).
10. Kuschner R, Heppner D, Andersen S et al. Azithromycin prophylaxis against a chloroquine resistant strain of Plasmodium falciparum. Lancet 343(8910), 1396-1397 (1994).
11. Anderson S, Berman J, Kuschner R et al. Prophylaxis of Plasmodium falciparum malaria with azithromycin administered to volunteers. Ann. Intern. Med. 123, 771-773 (1995).
12. Ohrt C, Willingmyre G, Lee P, Knirsch C and Milhous W. Assessment of azithromycin in combination with other antimalarial drugs against Plasmodium falciparum in vitro. Antimicrob. Agents Chemother. 46, 2518-2524 (2002).
13. Chico R M, Mayaud P, Ariti C, Mabey D, Ronsmans C, Chandramohan D. Prevalence of malaria and sexually transmitted and reproductive tract infections in pregnancy in sub-saharan Africa. JAMA 307(19), 2079-2086 (2012).
14. Williams JW. A textbook of obstetrics. D Appleton & Co, New York, USA 1923.
15. Ratnam AV, Din SN, Hira SK et al. Syphilis in pregnant women in Zambia. Br. J. Vener Dis. 58(6), 355-358 (1982).
16. Hay PE, Lamont RF, Taylor-Robinson D, Morgan DJ, Ison C and Pearson J. Abnormal bacterial colonisation of the genital tract and subsequent preterm delivery and late miscarriage. BMJ 308(6924), 295-298 (1994).
17. Leitich H, Bodner-Adler B, Brunbauer M, Kaider A, Egarter C, Husslein P. Bacterial vaginosis as a risk factor for preterm delivery: a meta-analysis. Am. J. Obstet. Gynecol. 189(1), 139-147 (2003).
18. Wilkowska-Trojniel M, Zdrodowska-Stefanow B, Ostaszewska-Puchalska I, Redzko S, Przepiesc J, Zdrodowski M. The influence of Chlamydia trachomatis infection on spontaneous abortions. Adv. Med. Sci. 54(1), 86-90 (2009).
19. McDermott J, Steketee R, Larsen S and Wirima J. Syphilis-associated perinatal and infant mortality in rural Malawi. Bull. World Health Organ. 71(6), 773-780 (1993).
20. Temmerman M, Gichangi P, Fonck K et al. Effect of a syphilis control programme on pregnancy outcome in Nairobi, Kenya. Sex. Transm. Infect. 76(2), 117-121 (2000).
21. Watson-Jones D CJ, Balthazar G, Weiss H et al. Syphilis in pregnancy in Tanzania. I. Impact of maternal syphilis on outcome of pregnancy. J. Infect. Dis. 186, 940-947 (2002).
22. Association of Chlamydia trachomatis and Mycoplasma hominis with intrauterine growth retardation and preterm delivery. The John Hopkins Study of Cervicitis and Adverse Pregnancy Outcome. Am. J. Epidemiol. 129(6), 1247-1257 (1989).
23. Watson-Jones D, Changalucha J, Gumodoka B et al. Syphilis in pregnancy in Tanzania. I. Impact of maternal syphilis on outcome of pregnancy. J. Infect. Dis. 186(7), 940-947 (2002).
24. Gravett MG, Nelson HP, DeRouen T, Critchlow C, Eschenbach DA and Holmes KK. Independent associations of bacterial vaginosis and Chlamydia trachomatis infection with adverse pregnancy outcome. JAMA 256(14), 1899-1903 (1986).
25. McGregor JA, French JI, Parker R et al. Prevention of premature birth by screening and treatment or common genital tract infections: results of a prospective controlled evaluation. Am. J. Obstet. Gynecol. 173(1), 157-167 (1995).
26. Blas MM, Canchihuaman FA, Alva IE, Hawes SE. Pregnancy outcomes in women infected with Chlamydia trachomatis: A population-based cohort study in Washington State. Sex. Transm. Infect. 83(4), 314-318 (2007).
27. Elliott B, Brunham RC, Laga M et al. Maternal gonococcal infection as a preventable risk factor for low birth weight. J. Infect. Dis. 161(3), 531-536 (1990).
28. Cotch MF, Pastorek JG 2nd, Nugent RP et al. Trichomonas vaginalis associated with low birth weight and preterm delivery. The vaginal infections and prematurity study group. Sex. Transm. Dis. 24(6), 353-360 (1997).
29. Svare JA, Schmidt H, Hansen BB, Lose G. Bacterial vaginosis in a cohort of Danish pregnant women: prevalence and relationship with preterm delivery, low birthweight and perinatal infections. BJOG 113(12), 1419-1425 (2006).
30. Odendaal HJ, Schoeman J, Grove D et al. The association between Chlamydia trachomatis genital infection and spontaneous preterm labour. S. Afr. J. Obstet. Gynaecol. 12(3), 146-149 (2006).
31. Watson-Jones D, Weiss HA, Changalucha JM et al. Adverse birth outcomes in United Republic of Tanzania-impact and prevention of maternal risk factors. Bull. World Health Organ. 85(1), 9-18 (2007).
32. Rours GI, Duijts L, Moll HA et al. Chlamydia trachomatis infection during pregnancy associated with preterm delivery: a population-based prospective cohort study. Eur. J. Epidemiol. 26(6), 493-502 (2011).
33. Johnson HL, Ghanem KG, Zenilman JM, Erbelding EJ. Sexually transmitted infections and adverse pregnancy outcomes among women attending inner city public sexually transmitted diseases clinics. Sex. Transm. Dis. 38(3), 167-171 (2011).
34. Donders GG, Desmyter J, De Wet DH, Van Assche FA. The association of gonorrhoea and syphilis with premature birth and low birthweight. Genitourin. Med. 69(2), 98-101 (1993).
35. Sutton MY, Sternberg M, Nsuami M, Behets F, Nelson AM, St Louis ME. Trichomoniasis in pregnant human immunodeficiency virus-infected and human immunodeficiency virus-uninfected congolese women: prevalence, risk factors, and association with low birth weight. Am J Obstet Gynecol, 181(3), 656-662 (1999).
36. Organization WH. Guidelines for the Management of Sexually Transmitted Infections. Switzerland (2003).
37. Hook EW 3rd, Stephens J, Ennis DM. Azithromycin compared with penicillin G benzathine for treatment of incubating syphilis. Ann. Intern. Med. 131(6), 434-437 (1999).
38. Klausner JD, Kohn RP, Kent CK. Azithromycin versus penicillin for early syphilis. N. Engl. J. Med. 354(2), 203-205, author reply 203-205 (2006).
39. Hook EW, 3rd, Martin DH, Stephens J, Smith BS and Smith K. A randomized, comparative pilot study of azithromycin versus benzathine penicillin G for treatment of early syphilis. Sex. Transm. Dis. 29(8), 486-490 (2002).
40. Kiddugavu MG, Kiwanuka N, Wawer MJ et al. Effectiveness of syphilis treatment using azithromycin and/or benzathine penicillin in Rakai, Uganda. Sex. Transm. Dis. 32(1), 1-6 (2005).
41. Riedner G, Rusizoka M, Todd J et al. Single-dose azithromycin versus penicillin G benzathine for the treatment of early syphilis. N. Engl. J. Med. 353(12), 1236-1244 (2005).
42. Hook EW, 3rd, Behets F, Van Damme K et al. A phase III equivalence trial of azithromycin versus benzathine penicillin for treatment of early syphilis. J. Infect. Dis. 201(11), 1729-1735 (2010).
43. Mitchell SJ, Engelman J, Kent CK, Lukehart SA, Godornes C, Klausner JD. Azithromycin-resistant syphilis infection: San Francisco, California, 2000-2004. Clin. Infect. Dis. 42(3), 337-345 (2006).
44. Lukehart SA, Godornes C, Molini BJ et al. Macrolide resistance in Treponema pallidum in the United States and Ireland. N. Engl. J. Med. 351(2), 154-158 (2004).
45. Marra CM, Colina AP, Godornes C et al. Antibiotic selection may contribute to increases in macrolide-resistant Treponema pallidum. J. Infect. Dis. 194(12), 1771-1773 (2006).
46. Grimes M, Sahi SK, Godornes BC et al. Two mutations associated with macrolide resistance in Treponema pallidum: increasing prevalence and correlation with molecular strain type in Seattle, Washington. Sex. Transm. Dis. 39(12), 954-958 (2012).
47. Chen XS, Yin YP, Wei WH et al. High prevalence of azithromycin resistance to Treponema pallidum in geographically different areas in China. Clin. Microbiol. Infect. 8(10), 1469-0691 (2012).
48. Wu H, Chang SY, Lee NY et al. Evaluation of macrolide resistance and enhanced molecular typing of Treponema pallidum in patients with syphilis in Taiwan: a prospective multicenter study. J. Clin. Microbiol. 50(7), 2299-2304 (2012).
49. Van Damme K, Behets F, Ravelomanana N et al. Evaluation of azithromycin resistance in Treponema pallidum specimens from Madagascar. Sex. Transm. Dis. 36(12), 775-776 (2009).
50. World Health Organization. Sexually transmitted and other reproductive tract infections: Guide to essential practice. Department of Reproductive Health and Research, World Health Organization, Geneva (2005).
51. Odugbemi T, Oyewole F, Isichei CS, Onwukeme KE and Adeyemi-Doro FA. Single oral dose of azithromycin for therapy of susceptible sexually transmitted diseases: a multicenter open evaluation. West Afr. J. Med. 12(3), 136-140 (1993).
52. Waugh MA. Open study of the safety and efficacy of a single oral dose of azithromycin for the treatment of uncomplicated gonorrhoea in men and women. J. Antimicrob. Chemother. 31(Suppl. E), 193-198 (1993).
53. Swanston WH, Prabhakar P, Barrow L, Mahabir BS, Furlonge C. Single dose (direct observed) azithromycin therapy for Neisseria gonorrhoeae and Chlamydia trachomatis in STD clinic attenders with genital discharge in Trinidad and Tobago. West Indian Med. J. 50(3), 198-202 (2001).
54. Lassus A. Comparative studies of azithromycin in skin and soft-tissue infections and sexually transmitted infections by Neisseria and Chlamydia species. J. Antimicrob. Chemother. 25(Suppl. A), 115-121 (1990).
55. Steingrimsson O, Olafsson JH, Thorarinsson H, Ryan RW, Johnson RB and Tilton RC. Azithromycin in the treatment of sexually transmitted disease. J. Antimicrob. Chemother. 25(Suppl. A), 109-114 (1990).
56. Steingrimsson O, Olafsson JH, Thorarinsson H, Ryan RW, Johnson RB and Tilton RC. Single dose azithromycin treatment of gonorrhea and infections caused by C. trachomatis and U. urealyticum in men. Sex. Transm. Dis. 21(1), 43-46 (1994).
57. Gruber F, Grubisic-Greblo H, Jonjic A et al. Treatment of gonococcal and chlamydial urethritis with azithromycin or doxycycline. Chron. Derm. (Roma) 5, 213-218 (1995).
58. Gruber F, Brajac I, Jonjic A, Grubisic-Greblo H, Lenkovic M, Stasic A. Comparative trial of azithromycin and ciprofloxacin in the treatment of gonorrhea. J. Chemother. 9(4), 263-266 (1997).
59. Rustomjee R, Kharsany AB, Connolly CA, Karim SS. A randomized controlled trial of azithromycin versus doxycycline/ciprofloxacin for the syndromic management of sexually transmitted infections in a resource-poor setting. J. Antimicrob. Chemother. 49(5), 875-878 (2002).
60. Der Simonian R, Laird N. Meta-analysis in clinical trials. Control Clin. Trials 7(3), 177-188 (1986).
61. Bignell C, Garley J. Azithromycin in the treatment of infection with Neisseria gonorrhoeae. Sex. Transm. Infect. 86(6), 422-426 (2010).
62. World Health Organization, London School of Hygiene and Tropical Medicine and International Trachoma Initiative. Trachoma control: A guide for programme managers. World Health Organization, Switzerland (2006).
63. Handsfield HH, Dalu ZA, Martin DH, Douglas JM Jr, McCarty JM, Schlossberg D. Multicenter trial of single-dose azithromycin vs. ceftriaxone in the treatment of uncomplicated gonorrhea. Azithromycin Gonorrhea Study Group. Sex. Transm. Dis. 21(2), 107-111 (1994).
64. Khaki P, Bhalla P, Sharma A, Kumar V. Correlation between In vitro susceptibility and treatment outcome with azithromycin in gonorrhoea: a prospective study. Indian J. Med. Microbiol. 25(4), 354-357 (2007).
65. Johnson SR, Sandul AL, Parekh M, Wang SA, Knapp JS, Trees DL. Mutations causing in vitro resistance to azithromycin in Neisseria gonorrhoeae. Int. J. Antimicrob. Agents 21(5), 414-419 (2003).
66. Martin I, Jayaraman G, Wong T, Liu G, Gilmour M, Canadian Public Health Laboratory N. Trends in antimicrobial resistance in Neisseria gonorrhoeae isolated in Canada: 2000-2009. Sex. Transm. Dis. 38(10), 892-898 (2011).
67. Martin I, Jayaraman G, Wong T, Liu G and Gilmour M. Trends in antimicrobial resistance in Neisseria gonorrhoeae isolated in Canada: 2000-2009. Sex. Transm. Dis. 38(10), 892-898. (2011).
68. Cole MJ, Chisholm SA, Hoffmann S et al. European surveillance of antimicrobial resistance in Neisseria gonorrhoeae. Sex. Transm. Infect. 86(6), 427-432 (2010).
69. Centers for Disease Control and Prevention. Neisseria gonorrhoeae with reduced susceptibility to azithromycin - San Diego County, California, 2009. MMWR Morb. Mortal. Wkly Rep. 60(18), 579-581 (2011).
70. Starnino S, Galarza P, Carvallo ME et al. Retrospective analysis of antimicrobial susceptibility trends (2000-2009) in Neisseria gonorrhoeae isolates from countries in Latin America and the Caribbean shows evolving resistance to ciprofloxacin, azithromycin and decreased susceptibility to ceftriaxone. Sex. Transm. Dis. 39(10), 813-821. (2012).
71. Khaki P, Bhalla P, Sharma P, Chawla R, Bhalla K. Epidemilogical analysis of Neisseria gonorrhoeae isolates by antimicrobial susceptibility testing, auxotyping and serotyping. Indian J. Med. Microbiol. 25(3), 225-229 (2007).
72. Sethi S, Golparian D, Bala M et al. Antimicrobial susceptibility and genetic characteristics of Neisseria gonorrhoeae isolates from India, Pakistan and Bhutan in 2007-2011. BMC Infect. Dis. 13, 35 (2013).
73. Kacmar J, Cheh E, Montagno A and Peipert JF. A randomized trial of azithromycin versus amoxicillin for the treatment of Chlamydia trachomatis in pregnancy. Infect. Dis. Obstet. Gynecol. 9(4), 197-202 (2001).
74. Jacobson GF, Autry AM, Kirby RS, Liverman EM, Motley RU. A randomized controlled trial comparing amoxicillin and azithromycin for the treatment of Chlamydia trachomatis in pregnancy. Am. J. Obstet. Gynecol. 184(7), 1352-1354, discussion 1354-1356 (2001).
75. Wehbeh HA, Ruggeirio RM, Shahem S, Lopez G, Ali Y. Single-dose azithromycin for Chlamydia in pregnant women. J. Reprod. Med. 43(6), 509-514 (1998).
76. Adair CD, Gunter M, Stovall TG, McElroy G, Veille JC, Ernest JM. Chlamydia in pregnancy: a randomized trial of azithromycin and erythromycin. Obstet. Gynecol. 91(2), 165-168 (1998).
77. Gunter ME AC, Ernest JM, McElroy G. Azithromycin powder versus erythromycin in the treatment of chlamydial cervicitis in pregnancy. Infect. Dis. Obstet. Gynecol. 4(53) (1996).
78. Edwards MS, Newman RB, Carter SG, Leboeuf FW, Menard MK, Rainwater KP. Randomized clinical trial of azithromycin vs. erythromycin for the treatment of chlamydia cervicitis in pregnancy. Infect. Dis. Obstet. Gynecol. 4(6), 333-337 (1996).
79. Rosenn MF, Macones GA and Silverman NS. Randomized trial of erythromycin and azithromycin for treatment of chlamydial infection in pregnancy. Infect Dis Obstet Gynecol, 3(6), 241-244 (1995).
80. Bush MR and Rosa C. Azithromycin and erythromycin in the treatment of cervical chlamydial infection during pregnancy. Obstet. Gynecol. 84(1), 61-63 (1994).
81. Golden MR, Whittington WL, Handsfield HH et al. Effect of expedited treatment of sex partners on recurrent or persistent gonorrhea or chlamydial infection. N. Engl. J. Med. 352(7), 676-685 (2005).
82. Katz BP FD, Orr DP. Factors affecting chlamydial persistence or recurrence one and three months after treatment. Chlamydial infections. Proceedings of the ninth international symposium on human chlamydial infection. Stephens RS, Byrne GI, Christiansen G et al.(Eds). International Chlamydia Symposium, USA 35-38 (1998).
83. Horner P. The case for further treatment studies of uncomplicated genital Chlamydia trachomatis infection. Sex. Transm. Infect. 82(4), 340-343 (2006).
84. Samra Z, Rosenberg S, Soffer Y, Dan M. In vitro susceptibility of recent clinical isolates of Chlamydia trachomatis to macrolides and tetracyclines. Diag. Microbiol. Infect. Dis. 39(3), 177-179 (2001).
85. Somani J, Bhullar VB, Workowski KA, Farshy CE, Black CM. Multiple drug-resistant Chlamydia trachomatis associated with clinical treatment failure. J. Infect. Dis. 181(4), 1421-1427 (2000).
86. Lefevre JC and Lepargneur JP. Comparative in vitro susceptibility of a tetracycline-resistant Chlamydia trachomatis strain isolated in Toulouse (France). Sex. Transm. Dis. 25(7), 350-352 (1998).
87. Jones RB, Van der Pol B, Martin DH, Shepard MK. Partial characterization of Chlamydia trachomatis isolates resistant to multiple antibiotics. J. Infect. Dis. 162(6), 1309-1315 (1990).
88. Dreses-Werringloer U, Padubrin I, Zeidler H, Kohler L. Effects of azithromycin and rifampin on Chlamydia trachomatis infection in vitro. Antimicrob. Agents Chemother. 45(11), 3001-3008 (2001).
89. Donati M, Rodriguez Fermepin M, Olmo A, D'Apote L, Cevenini R. Comparative in-vitro activity of moxifloxacin, minocycline and azithromycin against Chlamydia spp. J. Antimicrob. Chemother. 43(6), 825-827 (1999).
90. Misyurina OY, Chipitsyna EV, Finashutina YP et al. Mutations in a 23S rRNA gene of Chlamydia trachomatis associated with resistance to macrolides. Antimicrob. Agents Chemother. 48(4), 1347-1349 (2004).
91. Rice RJ, Bhullar V, Mitchell SH, Bullard J, Knapp JS. Susceptibilities of Chlamydia trachomatis isolates causing uncomplicated female genital tract infections and pelvic inflammatory disease. Antimicrob. Agents Chemother. 39(3), 760-762 (1995).
92. Bhengraj AR, Vardhan H, Srivastava P, Salhan S, Mittal A. Decreased susceptibility to azithromycin and doxycycline in clinical isolates of Chlamydia trachomatis obtained from recurrently infected female patients in India. Chemotherapy 56(5), 371-377 (2010).
93. Kaul R, Kimani J, Nagelkerke NJ et al. Monthly antibiotic chemoprophylaxis and incidence of sexually transmitted infections and HIV-1 infection in Kenyan sex workers: a randomized controlled trial. JAMA 291(21), 2555-2562 (2004).
94. Luntamo M, Kulmala T, Mbewe B, Cheung YB, Maleta K, Ashorn P. Effect of repeated treatment of pregnant women with sulfadoxine-pyrimethamine and azithromycin on preterm delivery in Malawi: a randomized controlled trial. Am. J. Trop. Med. Hyg. 83(6), 1212-1220 (2010).
95. Wawer MJ, Sewankambo NK, Serwadda D et al. Control of sexually transmitted diseases for AIDS prevention in Uganda: a randomised community trial. Rakai Project Study Group. Lancet 353(9152), 525-535 (1999).
96. Cowan FM, Hargrove JW, Langhaug LF et al. The appropriateness of core group interventions using presumptive periodic treatment among rural Zimbabwean women who exchange sex for gifts or money. J. Acquir. Immune Defic. Syndr. 38(2), 202-207 (2005).
97. Hay PE. Therapy of bacterial vaginosis. J. Antimicrob. Chemother. 41(1), 6-9 (1998).
98. Eschenbach DA. Bacterial vaginosis: resistance, recurrence, and/or reinfection? Clin. Infect. Dis. 44(2), 220-221 (2007).
99. Schwebke JR and Desmond RA. A randomized trial of the duration of therapy with metronidazole plus or minus azithromycin for treatment of symptomatic bacterial vaginosis. Clin. Infect. Dis. 44(2), 213-219 (2007).
100. Cohen MS, Hoffman IF, Royce RA et al. Reduction of concentration of HIV-1 in semen after treatment of urethritis: implications for prevention of sexual transmission of HIV-1. AIDSCAP Malawi Research Group. Lancet 349(9069), 1868-1873 (1997).
101. McClelland RS, Wang CC, Mandaliya K et al. Treatment of cervicitis is associated with decreased cervical shedding of HIV-1. AIDS (Lond., Engl.), 15(1), 105-110 (2001).
102. Wang CC, McClelland RS, Reilly M et al. The effect of treatment of vaginal infections on shedding of human immunodeficiency virus type 1. J. Infect. Dis. 183(7), 1017-1022 (2001).
103. Price MA, Zimba D, Hoffman IF et al. Addition of treatment for trichomoniasis to syndromic management of urethritis in Malawi: a randomized clinical trial. Sex. Transm. Dis. 30(6), 516-522 (2003).
104. Gray RH, Wabwire-Mangen F, Kigozi G et al. Randomized trial of presumptive sexually transmitted disease therapy during pregnancy in Rakai, Uganda. Am. J. Obstet. Gynecol. 185(5), 1209-1217 (2001).
105. Aires FT, Soares RP and Bernardo WM. Efficacy of azithromycin on the treatment of syphilis. Rev. Assoc. Med. Bras. 56(5), 496 (2010).
106. Zhou P, Qian Y, Xu J, Gu Z and Liao K. Occurrence of congenital syphilis after maternal treatment with azithromycin during pregnancy. Sex. Transm. Dis. 34(7), 472-474 (2007).
107. Luntamo M, Kulmala T, Mbewe B, Cheung Y B, Maleta K, Ashorn P. Effect of Repeated Treatment of Pregnant Women with Sulfadoxine-Pyrimethamine and Azithromycin on Preterm Delivery in Malawi: A Randomized Controlled Trial. Am. J. Trop. Med. Hyg. 83, 1212-1220 (2010).
108. Kigozi GG, Brahmbhatt H, Wabwire-Mangen F et al. Treatment of Trichomonas in pregnancy and adverse outcomes of pregnancy: a subanalysis of a randomized trial in Rakai, Uganda. Am. J. Obstet. Gynecol. 189(5), 1398-1400 (2003).
109. Klebanoff MA, Carey JC, Hauth JC et al. Failure of metronidazole to prevent preterm delivery among pregnant women with asymptomatic Trichomonas vaginalis infection. N. Engl. J. Med. 345(7), 487-493 (2001).
110. Stringer E, Read JS, Hoffman I, Valentine M, Aboud S, Goldenberg RL. Treatment of trichomoniasis in pregnancy in sub-Saharan Africa does not appear to be associated with low birth weight or preterm birth. Samj South Afr. Med. J. 100(1), 58-64 (2010).
111. Brocklehurst P, Gordon A, Heatley E, Milan SJ. Antibiotics for treating bacterial vaginosis in pregnancy. Cochrane Database Syst. Rev. 1, CD000262 (2013).
112. Nugent RP, Krohn MA, Hillier SL. Reliability of diagnosing bacterial vaginosis is improved by a standardized method of gram stain interpretation. J. Clin. Microbiol. 29(2), 297-301 (1991).
113. World Health Organization and Special Programme for Research and Training in Tropical Diseases. The use of rapid syphilis tests. WHO, Geneva (2006).
114. World Health Organization. Global Prevalence and Incidence of Selected Curable Sexually Transmitted Infections: Overview and Estimates. World Health Organization, Geneva (2001).
115. Mayaud P, ka-Gina G, Cornelissen J et al. Validation of a WHO algorithm with risk assessment for the clinical management of vaginal discharge in Mwanza, Tanzania. Sex. Transm. Infect. 74(Suppl. 74), S77-S84 (1998).
116. Vuylsteke B, Laga M, Alary M et al. Clinical algorithms for the screening of women for gonococcal and chlamydial infection: evaluation of pregnant women and prostitutes in Zaire. Clin. Infect. Dis. 17(1), 82-88 (1993).
117. Costello Daly C, Wangel AM, Hoffman IF et al. Validation of the WHO diagnostic algorithm and development of an alternative scoring system for the management of women presenting with vaginal discharge in Malawi. Sex. Transm. Infect. 74(Suppl. 74), S50-S58 (1998).
118. Tann CJ, Mpairwe H, Morison L et al. Lack of effectiveness of syndromic management in targeting vaginal infections in pregnancy in Entebbe, Uganda. Sex. Transm. Infect. 82(4), 285-289 (2006).
119. Chico RM, Ariti C, Cano J, Chandramohan D, Greenwood B. Malaria transmission intensity and the protective effect of intermittent preventive therapy using sulphadoxine-pyrimethamine. Evidence Review Group of the World Health Organization (2013).
120. Temmerman M, Njagi E, Nagelkerke N, Ndinya-Achola J, Plummer FA, Meheus A. Mass antimicrobial treatment in pregnancy. A randomized, placebo-controlled trial in a population with high rates of sexually transmitted diseases. J. Reprod. Med. 40(3), 176-180 (1995).
121. Elliott B, Brunham RC, Laga M et al. Maternal gonococcal infection as a preventable risk factor for low birth weight. J. Infect. Dis. 161(3), 531-536 (1990).
122. Johnson HL, Ghanem KG, Zenilman JM, Erbelding EJ. Sexually transmitted infections and adverse pregnancy outcomes among women attending inner city public sexually transmitted diseases clinics. Sex. Transm. Dis. 38(3), 167-171 (2011).
123. Silveira MF, Ghanem KG, Erbelding EJ et al. Chlamydia trachomatis infection during pregnancy and the risk of preterm birth: A case-control study. Int. J. STD AIDS 20(7), 465-469 (2009).
124. Blas MM, Canchihuaman FA, Alva IE, Hawes SE. Pregnancy outcomes in women infected with Chlamydia trachomatis: A population-based cohort study in Washington State. Sex. Transm. Infect. 83(4), 314-318 (2007).
125. Kovacs L, Nagy E, Berbik I, Meszaros G, Deak J, Nyari T. The frequency and the role of Chlamydia trachomatis infection in premature labor. Int. J. Gynaecol. Obstet. 62(1), 47-54 (1998).
126. Investigators of the Johns Hopkins Study of Cervicitis and Adverse Pregnancy Outcome. Association of Chlamydia trachomatis and Mycoplasma hominis with intrauterine growth retardation and preterm delivery. Am. J. Epidemiol. 129, 1247-1257 (1989).
127. Meis PJ, Goldenberg RL, Mercer B et al. The preterm prediction study: significance of vaginal infections. National Institute of Child Health and Human Development Maternal-Fetal M edicine Units Network. Am. J. Obstet. Gynecol. 173(4), 1231-1235 (1995).
128. Minkoff H, Grunebaum AN, Schwarz RH et al. Risk factors for prematurity and premature rupture of membranes: a prospective study of the vaginal flora in pregnancy. Am. J. Obstet. Gynecol. 150(8), 965-972 (1984).
129. Hillier SL, Nugent RP, Eschenbach DA et al. Association between bacterial vaginosis and preterm delivery of a low-birth-weight infant. The Vaginal Infections and Prematurity Study Group. N. Engl. J. Med. 333(26), 1737-1742 (1995).
130. Kiddugavu MG, Kiwanuka N, Wawer MJ et al. Effectiveness of syphilis treatment using azithromycin and/or benzathine penicillin in Rakai, Uganda. Sex. Transm. Dis. 32(1), 1-6 (2005).
131. Hook EW 3rd, Stephens J, Ennis DM. Azithromycin compared with penicillin G benzathine for treatment of incubating syphilis. Ann. Int. Med. 131(6), 434-437 (1999).
132. Riedner G, Rusizoka M, Todd J et al. Single-dose azithromycin versus penicillin G benzathine for the treatment of early syphilis. N. Engl. J. Med. 353(12), 1236-1244 (2005).
133. Chen CY, Chi KH, Pillay A, Nachamkin E, Su JR, Ballard RC. Detection of the A2058G and A2059G 23S rRNA gene point mutations associated with azithromycin resistance in Treponema pallidum by use of a TaqMan real-time multiplex PCR assay. J. Clin. Microbiol. 51(3), 908-913 (2013).
134. Muller EE, Paz-Bailey G and Lewis DA. Macrolide resistance testing and molecular subtyping of Treponema pallidum strains from southern Africa. Sex. Transm. Infect. 88(6), 470-474 (2012).
135. The A2058G Prevalence Workgroup. Prevalence of the 23S rRNA A2058G point mutation and molecular subtypes in Treponema pallidum in the United States,2007. to 2009. Sex. Transm. Dis. 39(10), 794-798 (2012).
136. Matejkova P, Flasarova M, Zakoucka H et al. Macrolide treatment failure in a case of secondary syphilis: a novel A2059G mutation in the 23S rRNA gene of Treponema pallidum subsp. pallidum. J. Med. Microbiol. 58(Pt 6), 832-836 (2009).
137. Martin IE, Gu W, Yang Y, Tsang RS. Macrolide resistance and molecular types of Treponema pallidum causing primary syphilis in Shanghai, China. Clin. Infect. Dis. 49(4), 515-521 (2009).
138. Tipple C, McClure MO, Taylor GP. High prevalence of macrolide resistant Treponema pallidum strains in a London centre. Sex. Transm. Infect. 87(6), 486-488 (2011).
139. Rekart ML, Patrick DM, Chakraborty B et al. Targeted mass treatment for syphilis with oral azithromycin. Lancet 361(9354), 313-314 (2003).
140. Muldoon EG, Walsh A, Crowley B, Mulcahy F. Treponema pallidum azithromycin resistance in Dublin, Ireland. Sex. Transm. Dis. 39(10), 784-786. (2012).
141. Martin IE, Tsang RS, Sutherland K et al. Molecular typing of Treponema pallidum strains in western Canada: predominance of 14d subtypes. Sex. Transm. Dis. 37(9), 544-548 (2010).
142. Morshed MG and Jones HD. Treponema pallidum macrolide resistance in BC. CMAJ 174(3), 349 (2006).
143. Khaki P, Bhalla P, Sharma A, Kumar V. Correlation between In vitro susceptibility and treatment outcome with azithromycin in gonorrhoea: a prospective study. Indian J. Med. Microbiol. 25(4), 354-357 (2007).
144. Olsen B, Pham TL, Golparian D, Johansson E, Tran HK, Unemo M. Antimicrobial susceptibility and genetic characteristics of Neisseria gonorrhoeae isolates from Vietnam, 2011. BMC Infect. Dis. 13, 40 (2013).
145. Lahra MM. Annual report of the Australian Gonococcal Surveillance Programme, 2011. Commun. Dis. Intell. Q Rep. 36(2), E166-E173. (2012).
146. Lo JY, Ho KM, Lo AC. Surveillance of gonococcal antimicrobial susceptibility resulting in early detection of emerging resistance. J. Antimicrob. Chemother. 67(6), 1422-1426 (2012).
147. Lefebvre B, Bourgault AM. P1- S1.44 Antimicrobial susceptibility profile of Neisseria gonorrhoeae isolates in the Province of Quebec - 2010. Sex. Transm. Infect. 87 (Suppl. 87), A117 (2011).
148. Hottes TS, Lester RT, Hoang LM et al. Cephalosporin and azithromycin susceptibility in Neisseria gonorrhoeae isolates by site of infection, British Columbia, 2006 to 2011. Sex. Transm. Dis. 40(1), 46-51 (2013).
149. Yuan LF, Yin YP, Dai XQ et al. Resistance to azithromycin of Neisseria gonorrhoeae isolates from 2 cities in China. Sex. Transm. Dis. 38(8), 764-768 (2011).
150. Takahashi S, Kurimura Y, Hashimoto J et al. Antimicrobial susceptibility and penicillin-binding protein 1 and 2. mutations in Neisseria gonorrhoeae isolated from male urethritis in Sapporo, Japan. J. Infect. Chemother. 19(1), 50-56 (2013).
151. Herchline TE, Inkrott BP. Resistance trends in Neisseria gonorrhoeae in southwestern Ohio. Sex. Transm. Dis. 37(2), 121-122 (2010).
152. Olsen B, Mansson F, Camara C et al. Phenotypic and genetic characterisation of bacterial sexually transmitted infections in Bissau, Guinea-Bissau, West Africa: a prospective cohort study. BMJ Open. 2(2), e000636 (2012).
153. Tanaka M, Koga Y, Nakayama H et al. Antibiotic-resistant phenotypes and genotypes of Neisseria gonorrhoeae isolates in Japan: identification of strain clusters with multidrug-resistant phenotypes. Sex. Transm. Dis. 38(9), 871-875 (2011).
154. Bala M. Characterization of profile of multidrug-resistant Neisseria gonorrhoeae using old and new definitions in India over a decade: 2000-2009. Sex. Transm. Dis. 38(11), 1056-1058 (2011).
155. Chisholm SA, Neal TJ, Alawattegama AB, Birley HD, Howe RA, Ison CA. Emergence of high-level azithromycin resistance in Neisseria gonorrhoeae in England and Wales. J. Antimicrob. Chemother. 64(2), 353-358 (2009).
156. Khaki P, Bhalla P, Sharma P, Chawla R, Bhalla K. Epidemilogical analysis of Neisseria gonorrhoeae isolates by antimicrobial susceptibility testing, auxotyping and serotyping. Indian J. Med. Microbiol. 225-229 (2007).
157. Enders M, Turnwald-Maschler A, Regnath T. Antimicrobial resistance of Neisseria gonorrhoeae isolates from the Stuttgart and Heidelberg areas of southern Germany. Eur. J. Clin. Microbiol. Infect. Dis. 25(5), 318-322 (2006).
158. Vorobieva V, Firsova N, Ababkova T et al. Antibiotic susceptibility of Neisseria gonorrhoeae in Arkhangelsk, Russia. Sex. Transm. Infect. 83(2), 133-135 (2007).
159. Sutrisna A, Soebjakto O, Wignall FS et al. Increasing resistance to ciprofloxacin and other antibiotics in Neisseria gonorrhoeae from East Java and Papua, Indonesia, in 2004. - implications for treatment. J. Clin. Pathol. 60(1), 90-91 (2007).
160. Martin IM, Hoffmann S, Ison CA. European Surveillance of Sexually Transmitted Infections (ESSTI): the first combined antimicrobial susceptibility data for Neisseria gonorrhoeae in Western Europe. J. Antimicrob. Chemother. 58(3), 587-593 (2006).
161. Chaudhary C, Hasan Chaudhary FA, Pandy AR et al. A pilot study on antimicrobial susceptibility of Neisseria gonorrhoeae isolates from Nepal. Sex. Transm. Dis. 32(10), 641-643 (2005).
162. Chen PL, Hsieh YH, Lee HC et al. Suboptimal therapy and clinical
163. Hsueh PR, Tseng SP, Teng LJ, Ho SW. High prevalence of ciprofloxacin-resistant Neisseria gonorrhoeae in Northern Taiwan. Clin. Infect. Dis. 40(1), 188-192 (2005).
164. Aydin D, Kucukbasmaci O, Gonullu N, Aktas Z. Susceptibilities of Neisseria gonorrhoeae and Ureaplasma urealyticum isolates from male patients with urethritis to several antibiotics including telithromycin. Clin. Infect. Dis. 40(11), 1608-1616 (2005).
165. Moodley P, Pillay C, Goga R, Kharsany AB, Sturm AW. Evolution in the trends of antimicrobial resistance in Neisseria gonorrhoeae isolated in Durban over a 5. year period: impact of the introduction of syndromic management. J. Antimicrob. Chemother. 48(6), 853-859 (2001).
166. Kobayashi I, Kanayama A, Saika T et al. Tendency toward increase in the frequency of isolation of beta-lactamase-nonproducing Neisseria gonorrhoeae exhibiting penicillin resistance, and recent emergence of multidrug-resistant isolates in Japan. Pediatrics 112(1 Pt 1), 87-95 (2003).
167. Llanes R, Sosa J, Guzman D et al. Antimicrobial susceptibility of Neisseria gonorrhoeae in Cuba (1995-1999): implications for treatment of gonorrhea. Sex. Transm. Dis. 30(1), 25-29 (2003).
168. Sosa J, Ramirez-Arcos S, Ruben M et al. High percentages of resistance to tetracycline and penicillin and reduced susceptibility to azithromycin characterize the majority of strain types of Neisseria gonorrhoeae isolates in Cuba, 1995-1998. Sex. Transm. Dis. 30(5), 443-448 (2003).
169. Dillon JA, Rubabaza JP, Benzaken AS et al. Reduced susceptibility to azithromycin and high percentages of penicillin and tetracycline resistance in Neisseria gonorrhoeae isolates from Manaus, Brazil, 1998. Sex. Transm. Dis. 28(9), 521-526 (2001).
170. Zarantonelli L, Borthagaray G, Lee EH, Shafer WM. Decreased azithromycin susceptibility of Neisseria gonorrhoeae due to mtrR mutations. J. Antimicrob. Chemother. 44(3), 411-414 (1999).
171. Young H, Moyes A, McMillan A. Azithromycin and erythromycin resistant Neisseria gonorrhoeae following treatment with azithromycin. J. Antimicrob. Chemother. 39(5), 623-630. (1997).
172. Mehaffey PC, Putnam SD, Barrett MS, Jones RN. Evaluation of in vitro spectra of activity of azithromycin, clarithromycin, and erythromycin tested against strains of Neisseria gonorrhoeae by reference agar dilution, disk diffusion, and Etest methods. Clin. Infect. Dis. 22(2), 233-239. (1996).
173. Dillon JA, Li H, Sealy J, Ruben M, Prabhakar P. Antimicrobial susceptibility of Neisseria gonorrhoeae isolates from three Caribbean countries: Trinidad, Guyana, and St. Vincent. Sex. Transm. Dis. 28(9), 508-514 (2001).
174. van Rijsoort-Vos JH, Stolz E, Verbrugh HA, Kluytmans JA. In-vitro activity of a new quinolone (CP-99,219) compared with ciprofloxacin, pefloxacin, azithromycin and penicillin against Neisseria gonorrhoeae. J. Antimicrob. Chemother. 36(1), 215-218 (1995).
175. Ison CA, Roope NS, Dangor Y, Radebe F, Ballard R. Antimicrobial susceptibilities and serotyping of Neisseria gonorrhoeae in southern Africa: influence of geographical source of infection. Epidemiol. Infect. 110(2), 297-305 (1993).
176. Starnino S, Stefanelli P. Azithromycin-resistant Neisseria gonorrhoeae strains recently isolated in Italy. J. Antimicrob. Chemother. 63(6), 1200-1204 (2009).
177. Donegan EA, Wirawan DN, Muliawan P et al. Fluoroquinolone-resistant Neisseria gonorrhoeae in Bali, Indonesia: 2004. Sex. Transm. Dis. 33(10), 625-629 (2006).
178. Morris SR, Moore DF, Hannah PB et al. Strain typing and antimicrobial resistance of fluoroquinolone-resistant Neisseria gonorrhoeae causing a California infection outbreak. J. Clin. Microbiol. 47(9), 2944-2949 (2009).
179. Ieven M, Van Looveren M, Sudigdoadi S et al. Antimicrobial susceptibilities of Neisseria gonorrhoeae strains isolated in Java, Indonesia. Sex. Transm. Dis. 30(1), 25-29 (2003).
180. Centers for Disease C and Prevention. Fluoroquinolone-resistance in Neisseria gonorrhoeae, Hawaii, 1999, and decreased susceptibility to azithromycin in N. gonorrhoeae, Missouri, 1999. MMWR Morb. Mortal. Wkly Rep. 49(37), 833-837 (2000).
181. Bruck PE, Robertson C, Allan PS. Management of Neisseria gonorrhoeae infection over 12 months in a genitourinary medicine setting against British Association for Sexual Health and HIV auditable outcome measures. Int. J. STD AIDS 23(3), e30-e32 (2012).
182. Dan M, Mor Z, Gottliev S, Sheinberg B, Shohat T. Trends in antimicrobial susceptibility of Neisseria gonorrhoeae in Israel, 2002 to 2007, with special reference to fluoroquinolone resistance. Sex. Transm. Dis. 37(7), 451-453 (2010).
183. McLean CA, Wang SA, Hoff GL et al. The emergence of Neisseria gonorrhoeae with decreased susceptibility to Azithromycin in Kansas City, Missouri, 1999 to 2000. Sex. Transm. Dis. 31(2), 73-78 (2004).
184. Arreaza L, Vazquez F, Alcala B, Otero L, Salcedo C, Vazquez JA. Emergence of gonococcal strains with resistance to azithromycin in Spain. J. Antimicrob. Chemother. 51(1), 190-191 (2003).
185. Rahangdale L, Guerry S, Bauer HM et al. An observational cohort study of Chlamydia trachomatis treatment in pregnancy. Sex. Transm. Dis. 33(2), 106-110 (2006).
186. Miller JM. Efficacy and tolerance of single-dose azithromycin for treatment of chlamydial cervicitis during pregnancy. Infect. Dis. Obstet. Gynecol. 3(5), 189-192 (1995).
187. Ljubin-Sternak S, Mestrovic T, Vilibic-Cavlek T et al. In vitro susceptibility of urogenital Chlamydia trachomatis strains in a country with high azithromycin consumption rate. Folia Microbiol. 29, 29 (2012).
188. Donati M, Di Francesco A, D'Antuono A et al. In vitro activities of several antimicrobial agents against recently isolated and genotyped Chlamydia trachomatis urogenital serovars D through K. Antimicrob. Agents Chemother. 54(12), 5379-5380 (2010).
189. Hong KC, Schachter J, Moncada J, Zhou Z, House J, Lietman TM. Lack of macrolide resistance in Chlamydia trachomatis after mass azithromycin distributions for trachoma. Emerg. Infect. Dis. 15(7), 1088-1090 (2009).
190. Lefevre JC, Escaffre MC, Courdil M, Lareng MB. In vitro evaluation of activities of azithromycin, clarithromycin and sparfloxacin against Chlamydia trachomatis. Pathol. Biol. 41(4), 313-315 (1993).
191. Agacfidan A, Moncada J, Schachter J. In vitro activity of azithromycin (CP-62,993) against Chlamydia trachomatis and Chlamydia pneumoniae. Antimicrob. Agents Chemother. 37(9), 1746-1748 (1993).
192. Scieux C, Bianchi A, Chappey B, Vassias I, Perol Y. In-vitro activity of azithromycin against Chlamydia trachomatis. J. Antimicrob. Chemother. 7-10 (1990).
193. Somani J, Bhullar VB, Workowski KA, Farshy CE, Black CM. Multiple drug-resistant Chlamydia trachomatis associated with clinical treatment failure. J. Infect. Dis. 181(4), 1421-1427 (2000).
194. van den Broek NR, White SA, Goodall M et al. The APPLe Study: A Randomized, Community-Based, Placebo-Controlled T rial of Azithromycin for the Prevention of Preterm Birth, with Meta-Analysis. PLoS Med. 6(12), e1000191 (2009).
195. Luntamo M, Kulmala T, Cheung YB, Maleta K, Ashorn P. The effect of antenatal monthly sulphadoxine-pyrimethamine, alone or with azithromycin, on foetal and neonatal growth faltering in Malawi: a randomised controlled trial. Trop. Med. Int. Health 18(4), 386-397 (2013).
196. Chico RM, Chandramohan D. Azithromycin plus chloroquine: combination therapy for protection against malaria and sexually transmitted infections in pregnancy. Expert Opin. Drug Metab. Toxicol. 7(9), 1153-1167 (2011).
197. Labbe AC, Pepin J, Khonde N et al. Periodical antibiotic treatment for the control of gonococcal and chlamydial infections among sex workers in Benin and Ghana: a cluster-randomized placebocontrolled trial. Sex. Transm. Dis. 39(4), 253-259 (2012).
198. Wi T, Ramos ER, Steen R et al. STI declines among sex workers and clients following outreach, one time presumptive treatment, and regular screening of sex workers in the Philippines. Sex. Transm. Infect. 82(5), 386-391 (2006).
199. Williams BG, Taljaard D, Campbell CM et al. Changing patterns of knowledge, reported behaviour and sexually transmitted infections in a South African gold mining community. AIDS 17(14), 2099-2107 (2003).
200. Steen R, Vuylsteke B, DeCoito T et al. Evidence of declining STD prevalence in a South African mining community following a core-group intervention. Sex. Transm. Dis. 27(1), 1-8 (2000).
201. Jones BM, Kinghorn GR, Duerden BI. In vitro activity of azithromycin and erythromycin against organisms associated with bacterial vaginosis and chancroid. Eur. J. Clin. Microbiol. Infect. Dis. 7(4), 551-553 (1988).
202. Shanker S, Toohey M, Munro R. In vitro activity of seventeen antimicrobial agents against Gardnerella vaginalis. Eur. J. Clin. Microbiol. 1(5), 298-300 (1982).
203. Ridgway GL. A review of the in-vitro activity of roxithromycin against genital pathogens. J. Antimicrob. Chemother. 20 (Suppl. B), 7-11 (1987).
204. Dubreuil L. In-vitro comparison of roxithromycin and erythromycin against 900. anaerobic bacterial strains. J. Antimicrob. Chemother. 20(Suppl. B), 13-19 (1987).
205. Maskell JP, Sefton AM, Williams JD. Comparative in-vitro activity of azithromycin and erythromycin against Gram-positive cocci, Haemophilus influenzae and anaerobes. J. Antimicrob. Chemother. 25(Suppl. A), 19-24 (1990).
206. Chang SC, Chen YC, Luh KT, Hsieh WC. Macrolides resistance of common bacteria isolated from Taiwan. Diag. Microbiol. Infect. Dis. 23(4), 147-154 (1995).
207. Ednie LM, Spangler SK, Jacobs MR, Appelbaum PC. Antianaerobic activity of the ketolide RU 64004 compared to activities of four macrolides, five beta-lactams, clindamycin, and metronidazole. Antimicrob. Agents Chemother. 41(5), 1037-1041 (1997).
208. Mikamo H, Yin XH, Ninomiya M, Tamaya T. In vitro and in vivo antibacterial activities of telithromycin. Chemotherapy 49(1-2), 62-65 (2003).
209. Marina M, Ivanova M, Kantardjiev T. Antimicrobial susceptibility of anaerobic bacteria in Bulgaria. Anaerobe 15(4), 127-132 (2009).
210. Chen SC, Gottlieb T, Palmer JM, Morris G, Gilbert GL. Antimicrobial susceptibility of anaerobic bacteria in Australia. J. Antimicrob. Chemother. 30(6), 811-820 (1992).
211. Wexler HM, Molitoris E, Molitoris D, Finegold SM. In vitro activity of telithromycin (HMR 3647) against 502. strains of anaerobic bacteria. J. Antimicrob. Chemother. 47(4), 467-469 (2001).
212. Spiegel CA. Susceptibility of Mobiluncus species to 23 antimicrobial agents and 15. other compounds. Antimicrob. Agents Chemother. 31(2), 249-252 (1987).
213. ReMeD (Network for Medicine and Development). Essential Medicines: Madagascar. World Health Organization www.who.int/selection-medicines/country- lists/mdg/en/.